Vaccine for dengue could be available commercially as early as mid-2026. Indian Immunologicals Limited has finished the first phase of clinical trials to determine the safety of the vaccine, the company’s Managing Director K. Anand Kumar said. The second and third phases of trials to test the vaccine’s efficacy are expected to begin shortly. IIL is a wholly owned subsidiary of the National Dairy Development Board, established in 1982.
“We have completed phase 1 trial, [which is] to determine safety. It was very successful. There have been no adverse reports. We will start phase 2 and 3 trials soon,” Dr. Kumar said in an interaction with The Hindu in Chennai over the past weekend. The findings of the first phase have already been published in peer-reviewed journals, he said. “We should have completed the trial in December, but it was delayed by a few months. We wanted to release it in early 2026, but now, may be by mid-2026, we will be ready to release the vaccines,” he added.
“For dengue, we got the virus strains from the National Institute of Virology. May be by mid-2026 we will be ready to release the vaccines. We will release the results of the clinical trials,” he explained of the protocol requirements for any such scientific work.
